Severity
Low
FDA Drug recall · Reported May 31, 2023
Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Num…
Amneal Pharmaceuticals of New York, LLC recalled Methylprednisolone Acetate Injectable Suspension, USP 80 mg/mL, For Intramuscular, Intras… - a low-severity action.
Methylprednisolone Acetate Injectable Suspension, USP 80 mg/mL, For Intramuscular, Intras… was recalled by Amneal Pharmaceuticals of New York, LLC in May 31, 2023. Reason: Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted In…. Check the official notice for the remedy. Verify recall #D-0756-2023 with the FDA Drug before acting.
The recall
Amneal Pharmaceuticals of New York, LLC issued this low-severity FDA Drug recall-Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted In….
Sourced from official FDA Drug enforcement records. Verify recall #D-0756-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0756-2023) was formally reported on May 31, 2023, with the manufacturer initiating the action on May 8, 2023. It is classified under Low severity (Class III), with a current status of Terminated. Amneal Pharmaceuticals of New York, LLC is listed as the recalling firm, operating out of Brookhaven, NY. Federal records list the affected scope as 69,239 vials.
The documented reason for this recall is: Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 701… Distribution data in the federal record shows the product reached: Nationwide in the USA and PR. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
69,239 vials
Related Recalls
6
5 from same agency
Methylprednisolone Acetate Injectable Suspension, USP 80 mg/mL, For Intramuscular, Intrasynovial and Soft Tissue Injection Only, Not for Intravenous Use, 1 mL Single Dose Vial, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Parenteral Unit, Ahmedabad 382213, India, Amneal Pharamceuticals LLC, Bridgewater, NJ 08807, NDC 70121-1574-01.
Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 70121-1574-1.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0756-2023 |
| Date reported | May 31, 2023 |
| Date initiated | May 8, 2023 |
| Recalling firm | Amneal Pharmaceuticals of New York, LLC |
| Firm location | Brookhaven, NY |
| Affected scope | 69,239 vials |
| Distribution | Nationwide in the USA and PR |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported May 31, 2023. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.